• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Livent Corporation

    1/22/24 7:20:50 AM ET
    $LTHM
    Major Chemicals
    Industrials
    Get the next $LTHM alert in real time by email
    15-12G 1 dp205487_1512g.htm FORM 15-12G

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

    FORM 15

     

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION  

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) 

    OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number: 001-38694

     

     

     

    LIVENT CORPORATION* 

    (Exact name of registrant as specified in its charter)

     

     

     

    1818 Market Street 

    Philadelphia, Pennsylvania 19103 

    (215) 299-5900 

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Common Stock, par value $0.001 per share 

    (Title of each class of securities covered by this Form)

     

    None

     

    (Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

      Rule 12g-4(a)(1) ☒
      Rule 12g-4(a)(2) ☐
      Rule 12h-3(b)(1)(i) ☒
      Rule 12h-3(b)(1)(ii) ☐
      Rule 15d-6 ☐
      Rule 15d-22(b) ☐

      

    Approximate number of holders of record as of the certification or notice date: One (1)*

     

    * On January 4, 2024, pursuant to the terms of that certain Transaction Agreement, as amended by the Amendment to Transaction Agreement, dated as of August 2, 2023, the Second Amendment to Transaction Agreement, dated as of November 5, 2023 and the Third Amendment to Transaction Agreement, dated as of December 20, 2023 (as so amended, the “Transaction Agreement”), by and among Livent Corporation, a Delaware corporation (“Livent”), Allkem Limited, an Australian public company limited by shares (“Allkem”), Arcadium Lithium plc, a public limited company incorporated under the laws of the Bailiwick of Jersey (“Arcadium”), Lightning-A Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and Arcadium Lithium Intermediate IRL Limited, a private company limited by shares and incorporated and registered in Ireland (“Irish IntermediateCo”), the transactions contemplated by the Transaction Agreement were consummated by way of (a) a scheme of arrangement under Australian law (the “scheme”), pursuant to which each issued, fully paid ordinary share of Allkem held by Allkem shareholders was exchanged for (i) where the Allkem shareholder did not elect to receive ordinary shares, par value $1.00 per share, of Arcadium (each, an “Arcadium Share”), one Arcadium CHESS Depositary Instrument (a “CDI”) quoted on the Australian Stock Exchange, each CDI representing a beneficial ownership interest (but not legal title) in one Arcadium Share (with exceptions for certain jurisdictions in which Allkem shareholders received Arcadium Shares unless they elected otherwise) and (ii) where the Allkem shareholder elected to receive Arcadium Shares, one Arcadium Share (provided that, where an Allkem shareholder had a registered address in an ineligible jurisdiction, the ordinary shares of Allkem of such Allkem shareholder (an “ineligible Allkem shareholder”) were transferred to a sale nominee prior to the scheme implementation (as defined in the Transaction Agreement), and the sale nominee was then issued CDIs under the scheme and subsequently sold all of the CDIs issued to it and remitted a pro rata share of the net proceeds of the sale of all of the CDIs issued to the sale nominee to each ineligible Allkem shareholder), with Allkem becoming a wholly owned subsidiary of Arcadium and (b) a merger (the “merger”), whereby Merger Sub, a wholly owned subsidiary of Irish IntermediateCo (a direct wholly owned subsidiary of Arcadium) merged with and into Livent, with Livent surviving the merger as an indirect wholly owned subsidiary of Arcadium, and pursuant to which each share of Livent common stock, par value $0.001 per share, other than certain excluded shares, was converted into the right to receive 2.406 Arcadium Shares, and such Arcadium Shares were issued at the effective time of the merger.

     

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Livent Corporation has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

     

    LIVENT CORPORATION 

     

       
    Dated: January 22, 2024 By: /s/ Gilberto Antoniazzi
      Name:  Gilberto Antoniazzi
      Title:  Chief Financial Officer

     

    Get the next $LTHM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LTHM

    DatePrice TargetRatingAnalyst
    12/5/2023$18.00 → $15.00Neutral → Underweight
    Piper Sandler
    10/25/2023$33.00 → $19.00Overweight → Neutral
    Piper Sandler
    10/25/2023$27.00 → $21.00Hold → Buy
    Deutsche Bank
    5/11/2023$32.00Neutral → Buy
    B. Riley Securities
    5/11/2023$30.00Sector Weight → Overweight
    KeyBanc Capital Markets
    4/5/2023$29.00 → $27.00Neutral → Buy
    BofA Securities
    2/16/2023$26.00 → $29.00Buy → Neutral
    BofA Securities
    1/11/2023$26.00Underperform → Buy
    BofA Securities
    More analyst ratings